249 related articles for article (PubMed ID: 25002283)
1. [Hepatitis C therapy: a problem almost solved].
Rizzetto M
Recenti Prog Med; 2014 Jun; 105(6):225-6. PubMed ID: 25002283
[TBL] [Abstract][Full Text] [Related]
2. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus therapies.
Smith RE
Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
[No Abstract] [Full Text] [Related]
4. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
Vachon ML; Dieterich DT
Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of hepatitis C: current status and perspectives].
Pol S; Corouge M
Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
[TBL] [Abstract][Full Text] [Related]
6. New hepatitis C therapies: the toolbox, strategies, and challenges.
Pawlotsky JM
Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
[TBL] [Abstract][Full Text] [Related]
7. [Antiviral treatment of chronic hepatitis C].
Berger A
Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
[TBL] [Abstract][Full Text] [Related]
8. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
9. Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors.
Sacchini D; Craxì L; Refolo P; Minacori R; Cicchetti A; Gasbarrini A; Cammà C; Spagnolo AG;
Dig Liver Dis; 2015 May; 47(5):351-5. PubMed ID: 25534233
[TBL] [Abstract][Full Text] [Related]
10. Future hepatitis C virus treatment: interferon-sparing combinations.
Gane E
Liver Int; 2011 Jan; 31 Suppl 1():62-7. PubMed ID: 21205140
[TBL] [Abstract][Full Text] [Related]
11. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
Bublak R
MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics of new oral hepatitis C antiviral drugs.
Vispo E; Barreiro P; Soriano V
Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):5-16. PubMed ID: 23094639
[TBL] [Abstract][Full Text] [Related]
14. Future treatment of chronic hepatitis C.
Keeffe EB
Antivir Ther; 2007; 12(7):1015-25. PubMed ID: 18018759
[TBL] [Abstract][Full Text] [Related]
15. Advances in the management of hepatitis C.
Croagh CM; Lubel J
Intern Med J; 2013 Dec; 43(12):1265-71. PubMed ID: 24330361
[TBL] [Abstract][Full Text] [Related]
16. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
[TBL] [Abstract][Full Text] [Related]
17. Infectious diseases. First specific drugs raise hopes for hepatitis C.
Enserink M
Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
[No Abstract] [Full Text] [Related]
18. New developments in HCV therapy.
Kronenberger B; Zeuzem S
J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
20. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Rodríguez-Torres M
Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
